Skip to content. | Skip to navigation

Personal tools
Sections
You are here: Home Programs & Services Biological Safety IBC

Institutional Biosafety Committee Charter

Composition

The UC Davis IBC composition complies with the requirements of Section IV-B-1 of the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines).

 

Voting members:

  • Three not associated with the institution (community members)
  • The Campus Biological Safety Officer
  • At least one faculty expert in each of the research and biocontainment fields of study involving infectious agents or recombinant DNA conducted at UC Davis or UC Davis Health System (UCDHS).  This specifically includes members with expertise in plant rDNA research, animal rDNA research, and human gene transfer.
  • UC Davis and UCDHS staff experts in biological safety and biocontainment as appropriate

 

Ex officio, non-voting:

  • The Associate Vice Chancellor of Safety Services (Administrative and Resources Management)
  • The Attending Veterinarian
  • The Medical Director of the Davis campus Occupational Health Services
  • The Medical Director of UCDHS Occupational Health Services

 

Responsibilities

As required under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines), and under UC Davis Policy and Procedure 290-55, the IBC:

  • Reviews and evaluates all proposed research and other activities involving recombinant DNA technology at UC Davis, UC Davis Health System (UCDHS) and UC Davis satellite facilities.
  • Develops a risk assessment for each project to determine the containment requirements for each proposed project, to set the required biological safety level of the project, and to establish conditions with which the investigator must comply to conduct the activity.
  • Reviews human gene therapy (gene transfer) clinical trials proposed to be conducted at the UC Davis Medical Center (UCDMC) before any patients are enrolled to ensure the safety of staff members, health care providers, study enrollees and their family members, and other people who might be exposed to recombinant DNA materials.  Under the NIH Guidelines, Institutional Review Board approval of such human gene transfer clinical trials is contingent upon IBC approval.
  • Reviews all proposed research and other activities at UC Davis and UCDHS that involve potential exposure of susceptible human, animal, or plant hosts to infectious agents or to other biohazardous materials.  Such projects include research involving infectious agents or materials, teaching programs involving infectious agents or materials, archival collections of infectious agents or materials, or occupational exposures to potential biohazards.
  • Sets policy for the acquisition and safe handling, transfer, and storage of biohazardous agents and materials and recombinant DNA constructs on the Davis campus and in the UCDHS.
  • Reviews the operating performance and SOPs of each newly constructed or remodeled Biosafety Level 3 (BSL3) laboratory before the laboratory opens for use, and approves continued operation for each existing BSL3 laboratory for a maximum of one (1) year.

 

Meetings

The IBC meets on the third Monday of each month at 3:00 PM (fourth Monday in January and February).

 

Agendas and minutes:

The monthly IBC meeting agenda is distributed to the committee approximately seven days before the meeting date. The draft minutes from the previous month are usually distributed on the same date. The IBC minutes with proprietary or sensitive information redacted are available on request to members of the public.